Breast Cancer Radiation Therapy

Leaving radiotherapy out raised local recurrence tenfold. Ten year survival came out identical.

PRIME II randomized 1,326 women aged 65 and over, all with small hormone-receptor-positive node-negative tumors and all taking endocrine therapy, between whole breast radiotherapy and none at all. Local recurrence inside ten years was 9.5 percent without it and 0.9 percent with it. Overall survival at ten years was 80.8 percent and 80.7 percent. Both numbers are true and they mean different things.

Thirty years of this field has moved in one direction

Almost every change to breast radiotherapy since the 1990s has been a reduction. Fewer sessions. Smaller volumes of tissue treated. Lower total doses. In a defined group of patients, no radiotherapy at all.

Each of those reductions was tested against the longer or larger version in a randomized trial, and in each case the shorter or smaller option held its ground. That is unusual. Most of medicine moves by adding things.

That history matters when you are handed a plan, because a six-week course offered in 2026 for an ordinary early breast cancer is a course that was superseded twice. Ask why, and accept a specific answer about your own case. Real reasons exist. So does inertia.

What the treatment is buying, stated precisely

Radiotherapy after breast-conserving surgery reduces the chance the cancer comes back in the same breast. That is its first and most reliable effect. Whether it also extends life depends entirely on who is being treated, and conflating the two is how patients end up either frightened or falsely reassured.

Local control and survival are separate questions

PRIME II answers this as cleanly as any trial in oncology. Among 1,326 women aged 65 and over with hormone-receptor-positive, node-negative tumors of three centimeters or less, excised with clear margins and treated with endocrine therapy, omitting radiotherapy raised local recurrence within ten years from 0.9 percent to 9.5 percent, a hazard ratio of 10.4. Distant recurrence as a first event was no higher without radiotherapy, at 1.6 percent against 3.0 percent. Overall survival at ten years was 80.8 percent without and 80.7 percent with. Breast cancer specific survival did not differ either.

Where your own case sits on that spectrum

So in that population the treatment prevented recurrences in the breast and did not change how long women lived. Younger patients, larger or higher-grade tumors, involved nodes and hormone-receptor-negative disease are a different situation, where local control and survival are more tightly linked and where the case for treating is much stronger. Where you sit on that spectrum is the first thing to establish, and it is decided by your pathology report rather than by a general policy.

When leaving it out is a genuine option

Very few patients are told this is on the table. A narrow group of them should be.

Drag the table sideways on a narrow screen.

Why the endocrine therapy clause is not a detail

The women in PRIME II who avoided radiotherapy were all taking endocrine therapy, and that treatment is part of the reason their recurrence rate was as low as it was. Omitting radiotherapy and then stopping the tablets because of side effects is not the arrangement that was tested, and it is a common sequence in practice. Anyone considering this route should treat the endocrine therapy as the thing they have committed to, since a recurrence in the breast means a second operation and usually radiotherapy afterwards anyway, which is a worse year than the one the omission was meant to avoid.

The trade belongs to you and the decision does too. No department should make it quietly on your behalf in either direction.

One week instead of three, and which schedule to ask about

FAST-Forward recruited 4,096 patients across 97 UK centers after breast-conserving surgery or mastectomy, and randomized them three ways.

1. Forty grays in fifteen sessions over three weeks, which was the international standard at the time and had itself replaced a fifty-gray, twenty-five-session, five-week course.
2. Twenty-seven grays in five sessions over one week.
3. Twenty-six grays in five sessions over one week.

What separated the two five-session arms

At a median follow-up of just under six years, the primary endpoint of relapse in the treated breast had occurred in 31, 27 and 21 patients across the three groups, and both one-week schedules met the non-inferiority criterion against three weeks. Normal tissue effects separated them. Moderate or marked clinician-assessed effects in the breast or chest wall at five years were reported in 9.9 percent of the three-week group, 15.4 percent of the 27-gray group and 11.9 percent of the 26-gray group. Across all assessments from one to five years the odds ratio against three weeks was 1.55 for 27 grays and 1.12 for 26 grays, and patient and photographic assessments told the same story. The higher of the two one-week doses cost cosmetic outcome. The lower one did not. That distinction has practical consequences, because both five-fraction doses will appear in published protocols and in quotations, and a department quoting 27 grays is quoting the arm of the trial that came out worse on the outcome patients notice most.

So the answer that came out of the trial was specific. Twenty-six grays in five fractions rather than twenty-seven, and that one-gray difference is the whole point of running the trial with three arms.

Travel changes what this evidence is worth. It turns a three-week stay into a one-week stay for a large share of early breast cancer, so the five-fraction dose being proposed is the first thing to establish before anything else is booked.

Treating part of the breast, and whether you need a boost

The other reduction was in volume rather than time.

IMPORT LOW randomized 2,018 women aged 50 and over, with unifocal invasive ductal cancer of three centimeters or less, none to three positive nodes and margins of at least two millimeters, between whole breast treatment, a reduced dose to the whole breast with full dose to the tumor area, and partial breast treatment alone. All three used fifteen fractions. Five-year local relapse was 1.1 percent in the whole breast group, 0.2 percent in the reduced-dose group and 0.5 percent in the partial breast group, and both experimental approaches were non-inferior. Patients in the partial breast group reported significantly less change in breast appearance and significantly less hardening or firmness of the breast. What made that trial unusually easy to copy is that the partial breast technique used nothing exotic. It used the standard tangential beams shortened in length, which is why the authors could say the approach was implementable in radiotherapy centers worldwide, and why a department declining to offer it cannot blame its equipment.

The tumor bed boost, which is a separate question

Boost means extra dose to the area the tumor came from, added after the main course. It reduces local recurrence and it costs cosmetic outcome, so it belongs to patients whose recurrence risk is high enough to be worth that, which generally means younger age, higher grade, close margins or extensive in-situ disease alongside the invasive tumor. An older patient with a small low-grade tumor and wide margins is being offered a boost for no clear reason, and a boost added by default across a clinic is a habit rather than a decision. It also lengthens the course, which matters if you have traveled.

Whether the lymph node areas get treated

Treating the breast is one decision. Treating the nodal areas above and behind it is another, with its own trial and its own trade-off.

MA.20 randomized 1,832 women with node-positive or high-risk node-negative disease, all having had breast-conserving surgery and systemic therapy, between whole breast radiotherapy alone and whole breast radiotherapy plus regional nodal irradiation covering the internal mammary, supraclavicular and axillary nodes. At a median follow-up of 9.5 years, ten-year overall survival was 82.8 percent with nodal treatment and 81.8 percent without, which is no difference. Ten-year disease-free survival was 82.0 percent against 77.0 percent, a hazard ratio of 0.76 that was statistically significant. The added treatment also added harm. Grade 2 or worse acute pneumonitis rose from 0.2 percent to 1.2 percent, and lymphedema from 4.5 percent to 8.4 percent.

Lymphedema, which deserves naming rather than listing

Lymphedema deserves more than a place on a list. Swelling of the arm after nodal treatment is often permanent, it is managed rather than cured, and for someone whose work or life depends on that arm it is a serious cost. That does not make nodal treatment wrong. It makes it a decision that should be discussed with the arm in the room.

Radiotherapy after mastectomy

Removing the whole breast does not always remove the need for radiation.

Chest wall radiotherapy gets recommended when the risk of recurrence there or in the nodes stays high after surgery, which in practice means involved lymph nodes, a large tumor, or cancer reaching the surgical margin. The target becomes the chest wall and usually the nodal areas too, so the planning problem here resembles the nodal decision above far more closely than it resembles whole breast treatment.

Where reconstruction complicates things

Radiation and reconstruction interact, and the sequence matters. An implant placed before radiotherapy faces a higher rate of capsular contracture, infection and reconstruction failure, and the cosmetic result is less predictable than in an unirradiated reconstruction. Tissue from your own body tolerates radiation better than an implant does, and is still usually placed afterwards. None of that makes reconstruction impossible. The practical consequence is that the plastic surgeon and the radiation oncologist have to agree the order before the first operation, which requires somebody to have asked whether radiotherapy is likely while the surgical plan was still being drawn. A patient who has an implant placed and is then told radiotherapy is needed has been let down by a planning failure and not by the treatment itself, and that sequence is common enough to be worth guarding against personally.

Raise reconstruction at the first consultation, even if it feels premature.

The heart dose, and what lowers it

A population-based study of 2,168 women treated in Sweden and Denmark between 1958 and 2001 estimated each patient mean heart dose from her own radiotherapy chart and compared those who had major coronary events with those who did not. The rate of major coronary events rose by 7.4 percent for every gray of mean heart dose, with no apparent threshold. The increase began within five years and continued into the third decade. The average mean heart dose across that cohort was 4.9 grays, and the proportional increase per gray was the same in women with and without cardiac risk factors, which means women who already had heart disease carried the larger absolute risk. The study covered 963 women who had a major coronary event and 1,205 who did not, and the dose for each of them was reconstructed from her own treatment chart rather than estimated from an average, which is the reason the dose-response curve it produced has held up as well as it has.

Those women were treated with older techniques. Modern planning achieves far lower heart doses, and the finding is what drove that change.

Scroll the table sideways if your screen is narrow.

What to ask for if your cancer is on the left

Left-sided cancers carry the most heart dose, so anyone with a left-sided tumor should ask directly what their mean heart dose in grays comes to and which of these techniques the department uses. A department that treats left breasts the same way it treats right ones has not engaged with the last decade of its own specialty.

What the sessions and the skin actually involve

Most of an appointment is spent getting you into exactly the position the plan was built around. The beam itself runs for a minute or two, and you feel nothing while it does. Fifteen minutes in the room is typical, and breath-hold technique adds a little to that.

Two things get missed. Radiation-induced fatigue behaves unlike ordinary tiredness and does not resolve with a good night of sleep, so light regular activity beats rest, and it fades over weeks to a couple of months. And breast tenderness or a firm area appearing months later needs examining rather than assuming, because distinguishing treatment change from recurrence is exactly what follow-up exists for.

The four questions that set your plan

Everything above reduces to four decisions. Each one has a trial behind it and an answer that depends on your pathology.

Four decisions, in the order they get made

1. Radiotherapy at all, or endocrine therapy alone. Relevant if you are over 65 with a small hormone-receptor-positive node-negative tumor, clear margins and a willingness to keep taking the tablets.
2. How long. One week at 26 grays in five fractions for most early disease after breast-conserving surgery, three weeks at 40 grays in fifteen where that suits the case better.
3. How much of the breast. Whole breast, or partial breast for lower-risk tumors in women over 50 who meet the size, grade, margin and node criteria.
4. Whether the nodal areas are included, which buys fewer recurrences and costs lymphedema and lung dose, and which applies to node-positive and high-risk node-negative disease.

Answering all four with reference to your own report makes it a plan. Answering all four the same way for every patient in the clinic makes it a protocol dressed up as one.

Four things on a plan that deserve a harder question

Each of these is common and none of them is automatic

One more, which cuts the other way. Be equally skeptical of anyone offering to omit radiotherapy in a patient who does not match the trial population, because the omission evidence is narrow and specific and does not stretch to cover younger women, larger tumors or involved nodes.

Having the course somewhere other than home

Of all the radiotherapy courses, breast treatment has become the one where traveling for it makes practical sense, and the five-fraction schedule did that.

How long you actually need to be here

Five-fraction treatment needs simulation, a planning gap of a few days, and then five consecutive weekday sessions, so around two weeks covers it comfortably. A three-week course needs closer to four weeks. Adding a tumor bed boost extends either one. Nodal treatment leaves the length alone and changes the planning, while post-mastectomy treatment follows the longer schedules far more than the shorter one. Get the intended total in writing before you book anything, because the difference between a two-week stay and a five-week stay changes the accommodation, the visa duration, the time you need away from work and whether somebody has to come with you, and none of those are things you want to rearrange from a hotel room in week two.

Follow-up once you are back home

Surveillance after breast radiotherapy runs for years, so the handover matters more here than the length of the stay does. Leave with the dose report including the mean heart dose, the treated volumes, the boost details if one was given, and a written schedule for mammography and clinical review, all in a form the person who follows you where you live can read without telephoning anyone. The plan should also name the new symptoms that warrant contact before the next appointment, which for this treatment means a new lump, skin change or nipple change in the treated breast, swelling or heaviness in the arm, and chest pain or breathlessness on exertion given what the dose-response above says about the heart. Write those down before you fly rather than trying to remember them, and ask for a copy to be sent to whoever will be seeing you at home, since a report that exists only in your own luggage tends to go missing in the year it is needed.

The six things that move the figure on a quotation

No prices appear on this page. A figure quoted before the pathology has been read amounts to a guess, and the variables behind the real total are straightforward enough to set out here, so that a quotation makes sense when one arrives.

Reading a quotation properly

Where the money actually goes

This table slides left and right on a small screen.

Request a quotation that separates planning, delivery, the boost if any, motion management and living costs. A single combined figure hides the one thing worth comparing, which is how many sessions you are actually paying for.

Breast cancer radiation therapy FAQ

References

• Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward). 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613-1626.
• Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in early breast cancer. New England Journal of Medicine. 2023;388(7):585-594.
• Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial). 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390(10099):1048-1060.
• Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional nodal irradiation in early-stage breast cancer. New England Journal of Medicine. 2015;373(4):307-316.
• Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. New England Journal of Medicine. 2013;368(11):987-998.